Trends in vaccine-preventable diseases

Seminars in Pediatric Infectious Diseases

Volumn 8, Issue 1, 1997, Pages 23-33

  Orenstein, W A ^a   Hadler, S ^a   Wharton, M ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; VARICELLA ZOSTER VACCINE;

CHILDHOOD DISEASE; COST BENEFIT ANALYSIS; DIPHTHERIA; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HERPES ZOSTER; HUMAN; MEASLES; PERTUSSIS; POLIOMYELITIS; REVIEW; RUBELLA; TETANUS; VACCINATION;

EID: 0031028167     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1870(97)80006-4     Document Type: Article

References (110)

1. King GE Markowitz LE Patriarca PA Clinical efficacy of measles vaccine during the 1990 measles epidemic Pediatr Infect Dis J 10 1991 883 887
2. Onorato IM Wassilak SG Meade B Efficacy of whole-cell pertussis vaccine in preschool children in the United States JAMA 267 1992 2745 2749
3. Wharton M Cochi SL Williams WW Measles, mumps, and rubella vaccine Infect Dis Clin North Am 4 1990 45 73
4. Orenstein WA Weisfeld JS Halsey NA Diphtheria and tetanus toxiods and pertussis vaccine, combined Halsey NA DeQuadros CA Recent Advances in Immunization, a Bibliographic Review. Scientific Publication No. 451 1983 Pan American Health Organization Washington, DC 30 51
5. Hadler SC Margolis HS Hepatitis B immunization: Vaccine types, efficacy, and indications for immunization Remington JS Swartz MN Current Topics in Clinical Infectious Diseases vol 12 1992 Blackwell Scientific Publications Cambridge, MA 283 308
6. Blacks B Shinefield HR Fireman BH Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOc) vaccine in a US population of 61,080 children Pediatr Infect Dis J 10 1991 97 104
7. Santosham M Wolff M Reid R The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neiseria meningitidis outermembrane protein complex N Engl J Med 324 1991 1767 1772
8. McBean AM Thoms ML Albrecht P Serologic response to oral polio vaccine and enhanced-potency inactivated vaccines Am J Epidemiol 128 1988 615 628
9. Centers for Disease Control and Prevention Progress toward elimination of Hacmophilus influenzae type b disease among infants and children: United States 1993–1994 MMWR 44 1995 545 550
10. Fox JP Elveback L Scott W Herd immunity: Basic concept and relevance to public health immunization practices Am J Epidemiol 94 1972 179 189
11. Copies may be obtained from the National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA Hatziandreu EJ Palmer CS Brown RE A cost benefit analysis of the diphtheria-tetanus-pertussis vaccine 1994 Battelle Arlington, VA
12. Lieu TA Cochi SL Black SB Cost effectiveness of a routine varicella vaccination program for US children JAMA 271 1994 375 381
13. Hinman AR Koplan JP Pertussis and pertusis vaccine: Further analysis of benefits, risk and costs Dev Biol Stand 61 1985 429 437
14. Copies may be obtained from the National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA Hatziandreu EJ Brown RE Halpern MT A cost benefit analysis of the measles-mumps-rubella vaccine 1994 Battelle Arlington, VA
15. Copies may be obtained from the National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA Hatziandreu EJ Palmer CS Halpern MT A cost benefit analysis of the oral polio vaccine 1994 Battelle Arlington, VA
16. Centers for Disease Control and Prevention: A cost benefit analysis of Hib vaccine (in preparation)
17. Cochi SL Broome CV Hightower AW Immunization of U.S. children with H. influenzae vaccine: A cost-effectiveness model of strategy assessment JAMA 253 1985 521 529
18. Cochi SL Broome CV Vaccine prevention of H. influenzae type b disease: Past, present and future Pediatr Infect Dis J 5 1986 12 19
19. Centers for Disease Control and Prevention National, state, and urban area vaccination coverage levels among children aged 19–35 months: United States, July 1994–June 1995 MMWR 45 1996 508 513
20. Centers for Disease Control and Prevention Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Advisory Committee on Immunization Practices MMWR 40 RR-13 1991 1 19
21. Sencer DJ Dull HB Langmuir AD Epidemiologic basis for eradication of measles in 1967 Public Health Rep 82 1967 253 256
22. Hinman AR Brandling-Bennett AD Nieberg PI The opportunity and obligation to eliminate measles from the United States JAMA 242 1979 1157 1162
23. Centers for Disease Control and Prevention Reported vaccinepreventalble diseases and the Childhood Immunization Initiative MMWR 43 1994 52 60
24. Atkinson WL Orenstein WA Krugman S The resurgence of measles in the United States, 1989–1990 Ann Rev Med 43 1992 451 463
25. Centers for Disease Control and Prevention Measles surveillance: United States, 1991 MMWR 41 6 1992 1 12
26. Centers for Disease Control and Prevention Measles: United States, 1995 MMWR 45 15 1996 305 307
27. Rota JS Heath JL Rota PA Molecular epidemiology of measles virus: Identification of pathways of transmission and implications for measles elimination J Infect Dis 173 1996 32 37
28. Hutchins S Markowitz L Atkinson W Measles outbreaks in the United States, 1987 through 1990 Pediatr Infect Dis J 15 1996 31 38
29. Centers for Disease Control Measles prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR 39 1989 1 18
30. (abstr) Vitek CR Redd SB Redd SC Trends in imported measels cases to the United States—1980–1994 Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA 1995
31. DeQuadros CA Olivé JM Hersh BS Measles elimination in the Americas: Evolving strategies JAMA 275 1996 224 229
32. Hersh BS Markowitz LE Maes EF The geographic distribution of measles in the United States, 1980 through 1989 JAMA 267 1992 1936 1941
33. Davis SF Strebel PM Atkinson WL Reporting efficiency duruing a measles outbreak in New York City, 1991 Am J Public Health 83 1993 1011 1015
34. Ewert DP Frederick PD Run GHF The reporting efficiency of measles by hospitals in Los Angeles county, 1986 and 1989 Am J Public Health 84 1995 868 869
35. Brown DWG Ramsay MEB Richards AF Salivary diagnosis of measles: A study of notified cases in the United Kingdom, 1991–1993 Br Med J 308 1994 1015 1017
36. Erdman DD Anderson LS Adams DR Evaluation of monoclinal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus J Clin Microbiol 29 1991 1466 1471
37. Lindegren ML Fehrs LJ Hadler SC Update: Rubella and congenital rubella syndrome 1980–1990 Epidemiol Rev 13 1991 341 348
38. Centers for Disease Control Increase in rubella and congenital rubella syndrome: United States, 1988–1990 MMWR 6 1991 93 99
39. Mellinger AK Cragan JD Atkinson WL High incidence of congenital rubella syndrome after a rubella outbreak Pediatr Infect Dis J 14 1995 573 578
40. Orenstein WA Bart KS Hinman AR The opportunity and obligation to eliminate rubella from the United States JAMA 251 1984 1988 1994
41. Institute of Medicine (U.S.) Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines Adverse effects of pertussis and rubella vaccines Howson CP Howe CJ Fineberg HV A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines 1991 National Academy Press Washington DC 187 197
42. Frenkel LM Nielsen K Garakian A A search for persistent rubella virus infection in persons with chronic symptoms after rubella and rubella immunization and in patients with juvenile rheumatoid arthritis Clin Infect Dis 22 1996 287 294
43. Session 117 Ray P Black S Shinefield H Retrospective cohort evaluation of chronic rubella vaccine arthropathy Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Orlando, FL October 1994 240
44. Kim-Farley RJ Bart KJ Schonberger LB Poliomyelitis in the United States: Virtual elimination of disease caused by wild virus Lancet 2 1984 1315 1317
45. Nathanson N Martin JR The epidemiology of poliomyelitis: Enigmas surrounding its appearance, epidemicity, and disappearance Am J Epidemiol 110 1979 672 692
46. Strebel PM Sutter RW Cochi SL Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease Clin Infect Dis 14 1992 568 579
47. (suppl) Schonberger LB Kaplan J Kim-Farley R Control of paralytic poliomyetisis in the United States Pediatr Infect Dis 6 1984 424 426
48. Prevots DR Sutter RW Strebel PM Completeness of reporting of paralytic poliomyelitis, United States 1980–1991: Implications for estimating the risk of vaccine-associated disease Arch Pediatr Adolesc Med 148 1994 479 485
49. Sutter RW Prevots DR Vaccine-associated paralytic poliomyelitis among immunodeficient persons Infect Med 11 426 1994 429 430
50. Sutter RW Prevots DR Vaccine-associated paralytic poliomyelitis among immunodeficient persons Infect Med 11 426 1994 435 438
51. Wyatt HV Poliomyelitis in hypogamma-globulinemics J Infect Dis 128 1973 802 806
52. Centers for Disease Control and Prevention Enhanced-potency inactivated poliomyelitis vaccine (supplementary statement): Recommendation of the Immunization Practices Advisory Committee (ACIP) MMWR 36 1987 795 798
53. Salt J Drucker JA Malvin D Noninfectious poliovirus vaccine Plotkin SA Mortimer EA Vaccines 1994 WB Saunders Philadelphia, PA 205 227
54. Salt J Drucker JA Malvin D Noninfectious poliovirus vaccine Plotkin SA Mortimer EA Vaccines 1994 WB Saunders Philadelphia, PA 205 227
55. De Quadros CA Andrus JK Olivé JM Polio eradication from the Western Hemisphere Annu Rev Public Health 13 1992 239 252
56. Resolution of the 41st World Health Assembly (WHO 41.28): Global eradication of poliomyelitis by the year 2000 May 13, 1988 World Health Organization Geneva, Switzerland
57. Centers for Disease Control and Prevention Update: Eradication of paralytic poliomyelitis in the Americas MMWR 41 1992 681 682
58. Centers for Disease Control and Prevention Certification of poliomyelitis elimination: The Americas, 1994 MMWR 43 1994 720 722
59. Hull HF Ward NA Hull BP Paralytic poliomyelitis: Seasoned strategies, disappearing disease Lancet 343 1994 1331 1337
60. Centers for Disease Control Pertussis: United States, January 1992–June 1995 MMWR 44 1995 525 529
61. Lambert HJ Epidemiology of a small pertussis outbreak in Kent County, Michigan Public Health Rep 80 1965 365 369
62. Bass JW Stephenson SR The return of pertussis Pediatr Infect Dis J 6 1987 141 144
63. Robertson PW Goldbert H Jarvie BH Bordetella pertussis infection: A cause of persistent cough in adults Med J Aust 146 1987 522 525
64. Mink CM Cherry JD Christenson P A search for Bordetella pertussis infection in university students Clin Infect Dis 14 1992 464 471
65. Wright SW Edwards KM Decker MD Pertussis infection in adults with persistent cough JAMA 273 1995 1044 1046
66. Nelson JD The changing epidemiology of pertussis in young infants Am J Dis Child 132 1978 371 373
67. Izurieta IS Kenyon TA Strebel PM Risk factors for pertussis in young infants during an outhreak in Chicago in 1993 Clin Infect Dis 22 1996 503 507
68. Greco D Salmaso S Mastrantonio P A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis N Engl J Med 334 1996 341 348
69. Gustafsson L Hallander HO Olin P A controlled trial of a two-component acelular, a five-component acellular, and a wholecell pertussis vaccine N Engl J Med 334 1996 349 355
70. Decker MD Edwards KM Steinhoff MC Comparison of 13 acellular pertussis vaccines: Adverse reactions Pediatrics 96 1995 557 566
71. Rosenthal S Chen R Hadler S The safety of acellular pertussis vs whole-cell pertussis vaccine: A postmarketing assessment Arch Pediatr Adolesc Med 150 1996 457 460
72. Trial synopses International Symposium on Pertussis Vaccine Trials Rome, Italy October 30–November 4, 1995
73. Schmitt HS Wirsing Von Konig CH Bogaerts H Efficacy of acellular pertussis vaccine in early childhood after household exposure JAMA 275 1996 37 41
74. Trolfors B Taranger J Lagergard T A placebo-controlled trial of a pertussis-toxoid vaccine N Engl J Med 333 1995 1045 1050
75. (in press) Orenstein WA Rapporteur's summary report International Symposium on Pertussis Vaccine Trials Rome, Italy Dev Biol Stand October 30–November 4, 1995
76. Wenger JD Pierce R Deaver KA Haemophilus influenzae vaccine efficacy study group: Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxid conjugate vaccine in US children aged 18–59 months Lancet 338 1991 395 398
77. Centers for Disease Control Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR 40 1991 1 7
78. Murphy TV White KE Pastor P Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination JAMA 269 1993 246 248
79. Broadhurst LE Erickson RL Kelley PW Decreases in invasive Haemophilus influenzae type b disease in U.S. army children 1984–1991 JAMA 269 1993 227 231
80. Takala AK Eskola J Leinonen M Reduction in oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine J Infect Dis 164 1991 982 986
81. Adams WG Deaver KA Cochi SL Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era JAMA 269 1993 221 226
82. Izurieta HS, Sutter RW, Strebel PM, et al: Epidemiology of tetanus: United States, 1991–1994. MMWR Surveillance Summaries (in press)
83. Gergen PH McQuillan GM Kiely M A population-based serologic survey of immunity to tetanus in the United States N Engl J Med 332 1995 761 766
84. Centers for Disease Control and Prevention: Adolescent immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American Medical Association (AMA). MMWR (in press)
85. Hardy IRB Dittman S Sutter RW Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union Lancet 347 1996 1739 1744
86. A. Centers for Disease Control and Prevention Update: Diphtheria epidemic—New independent states of the former Soviet Union, January 1995–March 1996 MMWR 95 1996 693 697
87. Sargent RK Rossing TH Downton SB Diphtheria immunity in Massachusetts: A study of three urban patient populations Am J Med Sci 287 1984 37 39
88. Weiss BP Strassburg MA Feeley JC Tetanus and diphtheria immunity in an elderly population in Los Angeles County Am J Public Health 73 1983 802 804
89. Cochi SL Preblud SR Orenstein WA Perspectives on the relative resurgence of mumps in the United States Am J Dis Child 142 1988 499 507
90. Hersh BS Fine PEM Kent WK Mumps outbreak in a highly vaccinated population J Pediatr 119 1991 187 193
91. Briss PA Fehrs LJ Parker RA Sustained transmission of mumps in a highly vaccinated population: Assessment of primary vaccine failure and waning vaccine-induced immunity J Infect Dis 169 1994 77 82
92. Centers for Disease Control and Prevention: Mumps surveillance United States, 1988–1993 MMW 44 3 1995 1 14
93. Pelosi JW, Besselink LC: Reducing mumps morbidity in Texas (abstr 213). Presented at 30th National Immunization Conference
94. Margolis HS Alter MJ Hadler SC Hepatitis B Evolving epidemiology and implications for control Semin Liver Dis 11 1991 84 92
95. Atlanta, GA Centers for Disease Control and Prevention Hepatitis Surveillance Report No. 55 1994
96. Atlanta, GA Centers for Disease Control and Prevention Hepatitis Surveillance Report No. 56 1995
97. (abstr) Goldstein S Alter M Moyer L The incidence and epidemiology of acute hepatitis B in the United States, 1989–1994 Proceedings of the IX Triennial Symposium on Viral Hepatitis and Liver Disease Rome, Italy 1996
98. Department of Labor, Occupational Safety and Health Administration Occupational exposure to blood-borne pathogens: Rules and regulations Federal Register 56 1991 64004 64182
99. Centers for Disease Control and Prevention Maternal hepatitis B screening practices: California, Connecticut, Kansas and the United States, 1992–1993 MMWR 43 1994 311
100. Centers for Disease Control and Prevention Maternal hepatitis B screening practices: California, Connecticut, Kansas and the United States, 1992–1993 MMWR 43 1994 317 320
101. Alter MJ Hadler SC Margolis HS The changing epidemiology of hepatitis B in the United States: Need for alternative vaccination strategies JAMA 263 1990 1218 1222
102. (suppl) Guess HA Broughton DD Melton LJ Population-based studies of varicella complications Pediatrics 78 1986 723 727
103. Jones SE Armstrong CB Bland C Varicella prevalence in day-care centers Pediatr Infect Dis J 14 1995 404 405
104. Wharton M The epidemiology of varicella zoster virus infections Infect Dis Clin North Am 10 1996 571 581
105. Committee on Infectious Diseases Recommendations for the use of live attenuated varicella vaccine Pediatrics 95 1995 791 796
106. Centers for Disease Control and Prevention Varicella prevention: Recommendations of the Advisory Committee on Immunization Practices MMWR 45 RR-11 1996
107. Halloran ME Cochi SL Lieu TA Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States Am J Epidemiol 140 1994 81 104
108. (abstr G11, 160) Eskola J Olander RM Litmanen L Hib antibody response after two doses of combined DTPa-Hib conjugate vaccine as compared to separate injections Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA September 17–20, 1995
109. Rennels MB Glass RI Dennehy PH Safety and efficacy of high-dose rhesus-human reassortment rotavirus vaccines: Report of the National Multicenter Trial Pediatrics 97 1996 7 13
110. Smith JC Haddix AC Teutsch SM Cost-effectiveness analysis of a rotavirus immunization program for the United States Pediatrics 96 1995 609 615